Hyperhidrosis

Meet the patient

A 19-year-old medical student cannot write an exam paper without smudging the ink, drops instruments on the ward, and changes her shirt twice before a tutorial. Her hands drip at the very thought of being watched. It has been this way since she was 12, her father has the same problem, and the sweating vanishes completely the moment she falls asleep. She has been told for years that it is "just anxiety."^[2][5]

Two questions sort her out: is this primary focal or secondary? (bilateral, symmetric, under 25, sleep-free, familial = primary) and which site, so which drug? (her palms mean iontophoresis, not just an antiperspirant). The diagnosis is clinical, the treatment is site-specific, and the relief — when you get it right — changes a life.^[3][6]

The first fork — primary focal versus secondary generalised

The single most important decision in hyperhidrosis is not which drug, but which disease: a benign overactive eccrine gland, or a hidden systemic illness. Get this wrong and you either miss a lymphoma or over-investigate a healthy 19-year-old.^[2]

^[2]

The BISSS rule pins primary focal disease — memorise it, because examiners ask for the five features:^[2]

^[2]

The classic trap: labelling a 55-year-old with new drenching night sweats and weight loss as "anxious." Sweating that does not stop in sleep, that is new, generalised or asymmetric, or that arrives after 25 with systemic symptoms, is secondary until you prove otherwise — and the next move is a work-up, not an antiperspirant.^[2][3]

The sympathetic-cholinergic paradox — the one viva answer

Eccrine glands are sympathetic, but their post-ganglionic fibre is cholinergic — it releases acetylcholine, not noradrenaline. This single anatomical quirk is the most tested fact in the topic, and it explains the entire pharmacology.^[4]

Thermoregulatory sweating is driven from the preoptic hypothalamus; emotional sweating from the limbic cortex and amygdala — which is why stress makes the palms drip in a cool room. Both descend to sympathetic preganglionic neurones in the thoracic lateral horn, synapse in the chain, and the post-ganglionic fibre releases acetylcholine onto M3 receptors on the eccrine clear cells, driving calcium, chloride and water into the duct. That chain is the target map for every drug:^[4]

• Aluminium chloride plugs the sweat duct at the stratum corneum and, with repeated use, atrophies the secretory coil.
• Botulinum toxin A blocks the calcium-dependent release of acetylcholine from the nerve terminal.
• Anticholinergics competitively block the M3 receptor (and every other muscarinic receptor — hence the side effects).
• Iontophoresis is thought to vasoconstrict and plug the duct with charged particles.
• Sympathectomy cuts the chain at T2–T4 — but the body redistributes its sweating elsewhere, which is the whole problem with it.^[1]

Primary focal disease reflects overactivity of the hypothalamic and limbic centres, not a structural gland defect — the glands are histologically normal but hyper-responsive, with a lowered threshold for emotional sweating and a strong familial clustering (some kindreds link to chromosome 14q).^[2]

How common, and how much it hurts

Hyperhidrosis is far commoner than patients — and many doctors — realise, and its quality-of-life toll rivals psoriasis. A US population survey put prevalence at about 2.8 percent; most never seek help, believing it is psychological or untreatable.^[5]

^{[5] [6]}

Severity is graded by the Hyperhidrosis Disease Severity Scale (HDSS): 1 never noticeable, 2 tolerable, 3 barely tolerable and frequently interfering, 4 intolerable and always interfering. A score of 3 or 4 is severe disease that warrants active treatment, and a fall of at least one point after therapy is clinically meaningful.^[6]

Secondary causes — the list you must run through

When the sweating is new, generalised or nocturnal, run this list before reaching for any drug — the treatment is the underlying cause.^[2][3]

^{[1] [2]}

Two named traps in the secondary list. First, phaeochromocytoma: episodic hypertension, pounding headache, palpitations, anxiety and sweating — test with 24-hour urinary or plasma fractionated metanephrines. Second, Parkinson disease is the commonest neurological cause of secondary hyperhidrosis, often with oily skin, seborrhoea and autonomic dysfunction — and the sweating can be drenching and paroxysmal.^[1][3]

Investigations — clinical first, bloods only when secondary

In a classic primary focal case, no investigations are needed — the diagnosis is clinical. Order the screening panel only when the presentation is atypical, new, generalised or accompanied by systemic symptoms.^[2][3]

The screening panel for suspected secondary disease: full blood count, inflammatory markers (CRP, ESR), glucose and HbA1c, thyroid function (TSH, free T4), liver and renal function, chest X-ray, and an HIV test after counselling. Targeted tests follow the suspected cause — plasma or urine metanephrines for phaeochromocytoma, 24-hour urinary 5-HIAA for carcinoid, IGRA for tuberculosis. A normal baseline screen does not exclude secondary disease if clinical suspicion is high.^[2][3]

The starch-iodine (Minor) test is the bedside map you use before botulinum toxin and to document response: dry the skin, paint with iodine, dust with cornstarch, and sweat turns the iodine-starch blue-black. A gravimetric variant weighs filter paper before and after a timed sweating period to quantify output.^[3]

Management — the site decides the drug

Treatment is site-specific and stepped: match the ladder to the anatomical subtype, and never start a systemic drug for disease a topical can control.^[3][4]

Axillary — aluminium chloride, then toxin, then miraDry

First-line is aluminium chloride hexahydrate 20 percent (Driclor, Anhydrol Forte). The trick that determines success: apply it to completely dry skin at night, let it dry, and wash it off in the morning — nightly for 3–7 nights until dry, then maintenance once or twice weekly. It fails most often because patients put it on wet skin or wash it off too soon. Side effects are irritation, stinging and folliculitis, mitigated by a short course of mild topical corticosteroid or a lower concentration.^[3][4]

Second-line is botulinum toxin A — 50 units per axilla (75 in some protocols), injected intradermally across the hair-bearing area. In the pivotal 52-week trial, three-quarters of patients on either dose improved by two points or more on the four-point HDSS, and the median effect lasted roughly six to seven months — repeat as needed. Third-line is microwave thermolysis (miraDry), a non-invasive, precisely controlled thermal treatment; in a recent series most patients needed only one session, and 95 percent had no or minimal sweating on objective testing afterwards. A topical glycopyrronium cloth or cream is a useful non-injectable alternative for those who cannot tolerate aluminium chloride.^{[4][10][7][8]}

Palmar and plantar — iontophoresis first

First-line for palms and soles is tap-water iontophoresis — a direct current of 15–20 mA through tap water for 20–30 minutes a session, 3–4 times weekly until dry then weekly maintenance. About 80–90 percent improve, it is safe and home-portable, and the only common side effect is transient tingling. Avoid it in pregnancy, epilepsy, pacemakers and metal implants near the site.^[3][4]

Aluminium chloride remains worth trying for palmar disease where iontophoresis is unavailable.^[3] Botulinum toxin works for the palm too, but the injections hurt, so they are often given after median and ulnar nerve blocks. Trials used 50–100 units per palm across about 20 intradermal sites; sweating falls within the first month and most patients are still improved at six months. Reserve it for iontophoresis failures.^[11][12]

Endoscopic thoracic sympathectomy is the last resort, and only for severe palmar disease — because of its feared complication. It interrupts the chain at T2–T4 and stops palmar sweating immediately in 95–98 percent, but compensatory hyperhidrosis hits 50–90 percent of patients and can be more disabling than the original disease; Horner syndrome, pneumothorax and neuralgia add to the risk. Modern T2-sparing techniques aim to cut compensatory sweating while keeping palmar efficacy. Counsel exhaustively, and never offer it for axillary or plantar disease as a primary treatment.^[4][9]

Generalised or multi-site — oral anticholinergics

Oral anticholinergics are reserved for generalised or multi-site disease that topical therapy cannot control.^[3][4]

^{[13] [14]}

The side-effect list is the reason these are not first-line for focal disease: dry mouth, blurred vision, constipation, urinary retention, tachycardia, heat intolerance (from reduced sweating), and confusion with oxybutynin. They are contraindicated in narrow-angle glaucoma, urinary retention, paralytic ileus and myasthenia gravis. Start low, go slow, and warn the patient about heat illness.^[3][4]

Gustatory and facial sweating

Gustatory sweating — face and scalp sweating with food, especially spicy meals — is often secondary: Frey syndrome after parotid surgery (parasympathetic fibres misdirected into the sympathetic pathway), or diabetic autonomic neuropathy. Manage with dietary modification, topical glycopyrronium, or intradermal botulinum toxin into the affected area; facial botulinum toxin needs care to avoid brow or eyelid ptosis.^[2]

How hyperhidrosis patients come to harm — the preventable list

• Missing a lymphoma or phaeochromocytoma by labelling new nocturnal generalised sweating as "anxiety."^[2]
• Aluminium chloride that "does not work" because it was applied to wet skin or washed off too soon — the commonest reason for apparent treatment failure.^[3]
• Oral anticholinergics started without screening for glaucoma, urinary retention or constipation.^[4]
• ETS offered without exhaustive counselling on compensatory hyperhidrosis — a 50–90 percent risk of an often irreversible, sometimes worse problem.^[9]
• Untreated depression and social avoidance in a disease whose quality-of-life toll rivals psoriasis.^[5]
• Heat illness in a patient rendered anhidrotic by anticholinergics in a hot climate.^[4]

Prognosis, disposition, and quality of life

Primary focal hyperhidrosis is chronic and lifelong, fluctuating in severity and often worst in the social pressure-cooker of adolescence and young adulthood; it may ease after middle age but rarely vanishes. With appropriate site-specific therapy most patients achieve substantial control. Secondary disease generally resolves when the cause is treated.^[2]

Disposition: most primary focal disease is managed in primary care with topical therapy and iontophoresis; dermatology referral for severe disease, first-line failure, botulinum toxin or miraDry; thoracic surgery only for severe refractory palmar disease after counselling; and specialist referral driven by the suspected secondary cause — endocrinology, oncology, neurology or infectious diseases.^[3]

Special populations

Children and adolescents: aluminium chloride and iontophoresis are both safe; botulinum toxin is used off-label at reduced doses; oral anticholinergics need caution, especially in hot climates; school liaison and psychological support matter.^[2]

Pregnancy and breastfeeding: aluminium chloride and iontophoresis are safe (minimal systemic absorption); botulinum toxin and oral anticholinergics are generally avoided unless benefits clearly outweigh risk. Reassurance and non-pharmacological measures come first.^[2]

The elderly: new-onset sweating is more likely secondary — keep a low threshold to investigate thyroid disease, diabetes, malignancy, infection and drugs. Avoid oxybutynin (confusion, falls); glycopyrrolate is better tolerated but still needs caution; prefer topical therapy and iontophoresis.^[1][3]

Diabetic patients: gustatory or generalised autonomic sweating from autonomic neuropathy — good glycaemic control is the foundation; macerated skin needs care to prevent bacterial and fungal infection.^[1]

Regional deltas

^[3]

The mantra, and the memory device

The mantra: primary is bilateral, symmetric, under 25 and sleep-free; secondary is new, generalised and nocturnal — investigate. Eccrine fibres are sympathetic but cholinergic, so aluminium chloride the axilla, iontophorese the palms, toxin the refractory, anticholinergic the generalised — and leave sympathectomy as the last, most counselled resort.^[2][4]

Ward-round test — three stems, thirty seconds each

Stem 1 — the dripping hands (answer)ShowHide

A 19-year-old student has bilateral dripping palms that began at 12, vanish in sleep, and worsen before exams; her father is the same. What is it, and what is the first treatment? Model: This is primary focal palmar hyperhidrosis — bilateral, symmetric, onset under 25, sleep-free, familial (the BISSS features). The diagnosis is clinical; no bloods are needed. First-line for palms is tap-water iontophoresis — 15–20 mA for 20–30 minutes, 3–4 times weekly until dry then maintenance. Aluminium chloride is less effective on thick palmar skin; botulinum toxin (with a nerve block) is reserved for iontophoresis failure. Reassure her it is not "just anxiety."^[2][4]

Stem 2 — the sweating 58-year-old (answer)ShowHide

A 58-year-old man has three months of drenching night sweats, 8 kg weight loss and fatigue. He has no history of excess sweating. What is the first move? Model: This is secondary generalised hyperhidrosis until proven otherwise — new, nocturnal, with systemic symptoms (weight loss) in an older adult. The first move is a work-up, not an antiperspirant: full blood count, inflammatory markers, LDH, chest X-ray and CT chest/abdomen/pelvis to exclude lymphoma (the B symptoms — fever, night sweats, weight loss — are the classic presentation). Add TSH, glucose, HIV test and a careful drug history. Treating the underlying cause resolves the sweating.^[2][5]

Stem 3 — episodic sweating with hypertension (answer)ShowHide

A 45-year-old has episodes of pounding headache, palpitations, anxiety and drenching sweating with a blood pressure of 190/110, then normal between attacks. What do you suspect, and what is the test? Model: This is phaeochromocytoma — episodic catecholamine surges producing the triad of headache, palpitations and sweating with paroxysmal hypertension. The best initial test is 24-hour urinary fractionated metanephrines or plasma free metanephrines; if positive, CT or MRI of the adrenals localises the tumour. Do not beta-block first (unopposed alpha vasoconstriction); start with an alpha-blocker once confirmed.^[2][3]

References14ShowHide

1. [1]Beitz JM. Parkinson's disease: a review Front Biosci (Schol Ed), 2014.PMID 24389262
2. [2]Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up J Am Acad Dermatol, 2019.PMID 30710604
3. [3]McConaghy JR, Fosselman D. Hyperhidrosis: Management Options Am Fam Physician, 2018.PMID 30215934
4. [4]Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options J Am Acad Dermatol, 2019.PMID 30710603
5. [5]Strutton DR, Kowalski JW, Glaser DA, et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey J Am Acad Dermatol, 2004.PMID 15280843
6. [6]Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee Dermatol Surg, 2007.PMID 17661933
7. [7]Wimmer F, Ramic A, Nolte JP, et al. Evaluation of Efficacy and Safety of miraDry(®) Procedure in the Treatment of Primary Axillary Hyperhidrosis Aesthetic Plast Surg, 2025.PMID 39753871
8. [8]Kim J, Han N, Koo H, et al. Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis Clin Drug Investig, 2026.PMID 41989535
9. [9]Delgado LM, D'Ambrosio PD, da Nobrega Oliveira REN, et al. T2-sparing vs T2-including sympathectomy for hyperhidrosis: a meta-analysis on compensatory sweating J Cardiothorac Surg, 2026.PMID 42351253
10. [10]Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety J Am Acad Dermatol, 2007.PMID 17306417
11. [11]Saadia D, Voustianiouk A, Wang AK, et al. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study Neurology, 2001.PMID 11739832
12. [12]Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis Br J Dermatol, 2003.PMID 14632812
13. [13]Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review J Eur Acad Dermatol Venereol, 2017.PMID 27976476
14. [14]Pariser DM, Krishnaraja J, Tremblay TM, et al. Randomized, placebo- and active-controlled crossover study of the safety and efficacy of THVD-102, a fixed-dose combination of oxybutynin and pilocarpine, in subjects with primary focal hyperhidrosis J Drugs Dermatol, 2017.PMID 28300854